TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) just unveiled an update.
Jacobio Pharmaceuticals Group Co., Ltd. has announced a capital increase and equity transfer agreement involving its subsidiaries and partners, including Oceanpine Capital. This strategic move allows Jacobio to focus on its core oncology therapies while optimizing capital allocation and enhancing organizational efficiency. The proceeds from the transaction will be used to advance the company’s Pan-KRAS inhibitor and other innovative oncology projects, aligning with its strategic goals and benefiting shareholders.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. operates in the pharmaceutical industry, focusing on the development and provision of innovative oncology therapies. The company is committed to improving health through its key pipeline products targeting various cellular pathways, including KRAS, MYC, P53, and tumor immunity.
Average Trading Volume: 9,736,748
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.23B
For an in-depth examination of 1167 stock, go to TipRanks’ Overview page.